Literature DB >> 21823280

[Clinical observation on ankylosing spondylitis treated with acupoint catgut embedding combined vessel pricking therapy].

Yuan-Sheng Tian1, Lei-Sheng Wang, Xin-Yi Wang, Wei-Qi Sun.   

Abstract

OBJECTIVE: To explore the efficacy and safety of acupoint catgut embedding combined with vessel pricking therapy for ankylosing spondylitis (AS).
METHODS: Eighty-six cases of AS were randomly divided into an acupoint catgut embedding combined vessel pricking group (group A) and a medication group(group B), 43 cases in each group. In the group A, acupoint catgut embedding combined with vessel pricking therapy were applied at Shenshu(BL 23), Dazhu (BL 11) and Jiaji (EX-B 2) etc. The group B was treated with oral administration of Sulfasalazine (SASP). The treatment lasted for 8 weeks. Symptom score, Visual Analogue Scale(VAS), the indices of morning stiff duration, Schober test, occiput to wall distance, chest expansion, erythrocyte sedimentation rate (ESR) and C-response protein (CRP) were compared before and after treatment between two groups.
RESULTS: After treatment, the total effective rate was 83.7% (36/43) in the group A, which was superior to that of 70.0% (28/40) in the group B (P < 0.05). The improvements of all indices in two groups were more significant than those before treatment (all P < 0.01), and symptom score, Schober test score and VAS score in group A were superior to those in the group B (P < 0.01, P < 0.05). No adverse reaction occurred in the group A.
CONCLUSION: The therapeutic effect of acupoint catgut embedding combined with vessel pricking therapy for AS is preferable without any adverse effects, which is superior to that of oral administration of SASP.

Entities:  

Mesh:

Year:  2011        PMID: 21823280

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  1 in total

1.  Clinical research on the efficacy and safety of thread-embedding acupuncture for treatment of herniated intervertebral disc of the lumbar spine: a protocol for a multicenter, randomized, patient-assessor blinded, controlled, parallel, clinical trial.

Authors:  Bonhyuk Goo; Dek-Woo Ryoo; Eun-Jung Kim; Dongwoo Nam; Hyun-Jong Lee; Jae-Soo Kim; Yeon-Cheol Park; Yong-Hyeon Baek; Byung-Kwan Seo
Journal:  Trials       Date:  2018-09-10       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.